SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Matsuura, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Matsuura, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages

K. Kobayashi

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

K. Tada

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

H. Itabe

Department of Biological Chemistry, Showa University School of Pharmaceutical Sciences, Tokyo, Japan

T. Ueno

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

P.-H. Liu

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

A. Tsutsumi

Division of Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan

M. Kuwana

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

T. Yasuda

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Y. Shoenfeld

Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Isreal, Incumbent of the Laura Schwarz-Kipp Chair for Research for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

P.G. de Groot

Thrombosis and Haemostasis Laboratory, Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht, The Netherlands

E. Matsuura

Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, eijimatu{at}md.okayama-u.ac.jp

Several interpretations have been made regarding the specificity of antiphospholipid antibodies and antibodies against oxidized low-density lipoprotein (oxLDL), but these are still controversial. In the present study, we delineated specificity of these two types of antibodies and analyzed their regulatory effect on oxLDL and/or β 2-glycoprotein I (β2GPI) binding to macrophages. Scavenger receptor-mediated binding of oxLDL (or its β2GPI complexes) to macrophages was observed and the binding was partly prevented by β 2GPI. The IgG monoclonal anti-β2GPI antibody (WB-CAL-1), which was derived from NZW x BXSB F1 mouse (a model of antiphospholipid syndrome), significantly increased the oxLDL/β2GPI binding to macrophages. In contrast, IgM anti-oxLDL natural antibody, EO6 (derived from apoe -/- mouse), prevented the binding. Different antigenic specificity of these antibodies to oxLDL and its β2GPI complexes was also confirmed in TLC—ligand blot and ELISA. Thus, IgG anti-β2 GPI autoantibodies contribute to lipid metabolism (housekeeping of oxLDL by macrophages) whereas IgM natural anti-oxLDL antibodies may protect against atherogenesis. In addition, in vitro data suggest that relatively high dose of intravenous immunoglobulin preparations (mainly contain IgG anti-oxLDL antibodies) might also prevent atherogenesis by inhibiting the oxLDL binding to macrophages. Lupus (2007) 16, 929—938.

Key Words: anticardiolipin antibody • antiphospholipid syndrome • atherosclerosis • β2-glycoprotein I • oxidized low-density lipoprotein

References

  • Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177—178.[Medline] [Order article via Infotrieve]
  • Galli M., Comfurius P., Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544—1547.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McNeil HP, Simpson RJ, Chesterman CN, Krilis SA Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120—4124.[Abstract/Free Full Text]
  • Bouma B., de Groot PG, van den Elsen JM et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166—5174.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257: 485—495.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337—3347.[Free Full Text]
  • George J., Harats D., Gilburd B. et al. Adoptive transfer of β2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822—1827.[Abstract/Free Full Text]
  • Yla-Herttuala S., Palinski W., Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086—1095.[Web of Science][Medline] [Order article via Infotrieve]
  • Lehtimaki T., Lehtinen S., Solakivi T. et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23—27.[Abstract/Free Full Text]
  • Yasunobu Y., Hayashi K., Shingu T., Yamagata T., Kajiyama G., Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 2001; 155: 445—453.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468—471.[Abstract/Free Full Text]
  • Palinski W., Horkko S., Miller E. et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-814.[Web of Science][Medline] [Order article via Infotrieve]
  • Shaw PX, Horkko S., Chang MK et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731—1740.[Web of Science][Medline] [Order article via Infotrieve]
  • Itabe H., Takeshima E., Iwasaki H. et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269: 15274—15279.[Abstract/Free Full Text]
  • Friedman P., Horkko S., Steinberg D., Witztum JL, Dennis EA Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J Biol Chem 2002; 277: 7010—7020.[Abstract/Free Full Text]
  • Itabe H., Yamamoto H., Suzuki M. et al. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 1996; 271: 33208—33217.[Abstract/Free Full Text]
  • Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569—573.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kobayashi K., Matsuura E., Liu Q. et al. A specific ligand for β2glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001; 42: 697—709.[Abstract/Free Full Text]
  • Liu Q., Kobayashi K., Furukawa J. et al. {omega}-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 2002; 43: 1486—1495.[Abstract/Free Full Text]
  • Kobayashi K., Kishi M., Atsumi T. et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 44: 716—726.[Abstract/Free Full Text]
  • Matsuura E., Kobayashi K., Tabuchi M., Lopez LR Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006; 45: 466—486.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923—935.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wu R., Svenungsson E., Gunnarsson I., Haegerstrand-Gillis C. et al. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and β2-glycoprotein I (β 2-GPI) in systemic lupus erythematosus. Clin Exp Immunol 1999; 115: 561—566.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hurez V., Kaveri SV, Kazatchkine MD Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J Autoimmun 1993; 6: 675—681.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Righi A., Schiavon F., Jablonska S. et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002; 61: 59—61.[Abstract/Free Full Text]
  • Shoenfeld Y., Katz U. IVIG therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123—137.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yuan Z., Kishimoto C., Sano H., Shioji K., Xu Y., Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol 2003; 285: H899—H906.[Abstract/Free Full Text]
  • Igarashi M., Matsuura E., Igarashi Y. et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 3262—3270.[Abstract/Free Full Text]
  • Hashimoto Y., Kawamura M., Ichikawa K. et al. Anticardiolipin antibodies in NZWxBXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149: 1063—1068.[Abstract]
  • Ichikawa K., Khamashta MA, Koike T., Matsuura E., Hughes GRV. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453—1461.[Web of Science][Medline] [Order article via Infotrieve]
  • Havel RJ, Eder HA, Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345—1353.[Web of Science][Medline] [Order article via Infotrieve]
  • Matsuura E., Inagaki J., Kasahara H. et al. Proteolytic cleavage of β 2glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol 2000; 12: 1183—1192.[Abstract/Free Full Text]
  • Matsuura E., Igarashi Y., Yasuda T., Triplett DA, Koike T. Anticardiolipin antibodies recognize β 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457—462.[Abstract/Free Full Text]
  • Kasahara H., Matsuura E., Kaihara K. et al. Antigenic structures recognized by anti-β2-glycoprotein I autoantibodies. Int Immunol 2005; 17: 1533—1542.[Abstract/Free Full Text]
  • Kuwana M., Matsuura E., Kobayashi K. et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005; 105: 1552—1557.[Abstract/Free Full Text]
  • Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β 2-glycoprotein in patients with antiphospholipid syndrome. Blood (in press).
  • Binder CJ, Horkko S., Dewan A. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736—743.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shoenfeld Y., Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 2004; 24: 107—114.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107: 387—393.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wu R., Shoenfeld Y., Sherer Y. et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations—possible immunomodulation of atherosclerosis. Autoimmunity 2003; 36: 91—97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Lupus, Vol. 16, No. 12, 929-938 (2007)
DOI: 10.1177/0961203307084170
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
N. Braun, N. Wade, E. Wakeland, and A. Major
Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr-/- mice
Lupus, December 1, 2008; 17(12): 1070 - 1078.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Matsuura, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Matsuura, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement